Head-to-head · free

Ovid Therapeutics Inc. vs uniQure

OVID vs QURE — return on capital, cash generation, margins and balance sheet side by side.

OVID

3 / 5

measures where OVID leads

QURE

2 / 5

measures where QURE leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureOVID · FY2025QURE · FY2025
Revenue$7.3M—
Net income(17.4M)(199.0M)
Revenue growth (yearly, multi-year)-68.1%-47.8%
Free cash flow(38.3M)(178.4M)
Free cash flow margin-528.6%—
Net cash / (debt)——
ROIC——
Return on equity-17.5%—
Gross margin—89.5%
Operating margin-585.2%-1166.8%
Net debt / EBITDA0.31x0.18x

Figures are as reported by each company; latest fiscal year shown.

Where Ovid Therapeutics Inc.'s cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full OVID profile →

Where uniQure's cash went (FY2025)

Capital spending
$439000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full QURE profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons